Skip to content

Codeine on Pharyngeal and Esophageal Motility

Effect of Codeine on Pharyngeal and Esophageal Motility in Healthy Subjects: a Double-blind, Placebo-controlled, Randomized, Cross-over Study

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03784105
Enrollment
22
Registered
2018-12-21
Start date
2017-09-07
Completion date
2018-12-14
Last updated
2018-12-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Esophageal Motility Disorders

Keywords

codeine, Esophageal motility, Pharyngeal motility

Brief summary

Opioids act on opioid receptors located in the brain as well as in the gastrointestinal (GI) tract to induce changes in motility. A variety of studies have linked chronic opioid use with changes in intestinal and to a lesser extent esophageal motility. Less is known about acute administration effects on distal esophageal motility and LES and even less with respect to proximal esophagus, UES and pharynx. Codeine, an opioid receptor agonist, by acting both centrally as well as in the periphery may induce changes in parts of the GI tract implicated in deglutition. Therefore, to evaluate the hypothesis the researchers will study motility patterns in the pharynx, UES, proximal and distal esophagus and LES in 22 healthy volunteers receiving placebo or codeine (60 mg) in a double-blind randomized cross-over controlled fashion. Motility patterns will be studied using state-of-the-art criteria and analytic tools (Chicago 3.0, AIMPlot analysis).

Interventions

30 mL of codeine phosphate 10mg/5mL

DRUGSiripus simplex

Sugar syrup

Sponsors

Universitaire Ziekenhuizen KU Leuven
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
OTHER
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Masking description

Double-blind, preparation and administration of codeine or placebo conducted by an independent researcher.

Intervention model description

Double-blind, placebo-controlled, randomized, cross-over study in healthy volunteers

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy volunteers aged between 18-60 years old * Written informed consent

Exclusion criteria

* No chronic disease/medication * No GI symptoms * Not pregnant or breast-feeding * No history of head/neck surgery * Not allergic to codeine

Design outcomes

Primary

MeasureTime frameDescription
Difference in distal contractile integral1 weekThe difference in distal contractile integral between the codeine and placebo condition
Difference in integrated relaxation pressure1 weekThe difference in integrated relaxation pressure between the codeine and placebo condition
Difference in distal latency1 weekThe difference in distal latency between the codeine and placebo condition.
Difference in pressure flow1 weekThe difference in pressure flow between the codeine and placebo condition

Countries

Belgium

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 17, 2026